Riskpilot← Back to searchSign inGet full accessPharmore Consulting AB
ABActiveOrg 55674775092:A Villagatan 5Business and other management consultancy activities · NACE 7020Est. 20082 employees
Revenue 2025
SEK 3,4M
-3% vs 2024
EBITDA margin
16.8%
-17% vs 2024
Equity ratio
70.7%
Financial strength
Net profit 2025
SEK 439K
-17% vs 2024
| Revenue | SEK 3,4M | -3% |
| EBITDA | SEK 578K | -17% |
| Net profit | SEK 439K | -17% |
| Total assets | SEK 1,1M | +6% |
| Equity | SEK 746K | +7% |
| Employees | 2 | — |
Legal name
Pharmore Consulting AB
Org number
5567477509
Legal form
Aktiebolag
NACE code
7020 · Business and other management consultancy activities
Founded
2 januari 2008
Share capital
SEK 100 000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget skall bedriva konsultationer inom organisationsutveckling och projektledning samt därmed förenlig verksamhet.
Address
2:A Villagatan 5
Phone
+46707678709
Email
malin@pharmoreconsulting.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 2 139 | 2 528 | 3 404 | 3 541 | 3 444 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 179 | 420 | 722 | 696 | 578 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 179 | 420 | 722 | 696 | 578 |
| Net financials | −1 | 41 | — | −2 | −1 |
| Profit before tax | 178 | 461 | 721 | 695 | 578 |
| Tax | −41 | −108 | −163 | −164 | −139 |
| Net profit | 137 | 353 | 558 | 531 | 439 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 718 | 671 | 965 | 992 | 1 055 |
| Equity | 265 | 468 | 666 | 697 | 746 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 453 | 203 | 299 | 295 | 310 |
| Total debt | 453 | 203 | 299 | 295 | 310 |
EBITDA margin
16.8%
This company
15.8%
Market median
+6% vs market
20212025
Equity ratio
70.7%
This company
38.2%
Market median
+85% vs market
20212025
Return on equity
58.8%
This company
18.4%
Market median
+220% vs market
20212025
Net profit margin
12.7%
This company
8.1%
Market median
+57% vs market
20212025
Asset turnover
3.26×
This company
1.12×
Market median
+191% vs market
20212025
Debt / equity
0.41×
This company
0.62×
Market median
+34% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
GA | Audit | 2022 |
EM Deputy Chief Executive Officer | Deputy Chief Executive Officer | 2022 |
MM Chief Executive Officer | Chief Executive Officer | 2022 |
No data on file.
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Pharmore Consulting AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Gesar Anna Karin Arlebrink | Audit | 0 companies |
| Elin Mathilda Törneland | Deputy Chief Executive Officer | 0 companies |
| Malin Marita Törneland | Chief Executive Officer | 0 companies |